Roivant's Mosliciguat Demonstrates Positive Phase 2 Efficacy for PH-ILD

Roivant announced positive results from its Phase 2 PHocus clinical trial for mosliciguat, a treatment for pulmonary hypertension associated with interstitial lung disease (PH-ILD). The study successfully met its primary endpoint by significantly reducing pulmonary vascular resistance and also showed improvements in secondary endpoints like six-minute walk distance. This is a crucial development for PH-ILD, a progressive and life-threatening condition with high unmet medical needs.